Vaxart Inc. Stock
Vaxart Inc. Stock
The Vaxart Inc. stock is trending slightly upwards today, with an increase of €0.000 (0.140%) compared to yesterday's price.
Our community identified positive and negative aspects for Vaxart Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vaxart Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Vaxart Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vaxart Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vaxart Inc. | 0.140% | -0.285% | -15.152% | -55.731% | -58.457% | -73.807% | -95.410% |
| Larimar Therapeutics Inc. | 1.190% | 6.623% | 8.784% | -48.889% | -13.441% | -6.395% | -83.088% |
| Achieve Life Sciences Inc. | 1.410% | -0.764% | -3.470% | -7.262% | 9.257% | 62.971% | -38.661% |
| aTyr Pharma Inc | -1.650% | 13.084% | 6.140% | -80.732% | -82.910% | -69.460% | -81.777% |
Comments
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for AVIR provided by MarketBeat
News
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart (OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a
